South San Francisco, CA – September 23, 2019 – Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

“This year has seen unrivalled scientific talent in the early-stage life sciences world and it has been a pleasure to for us at FierceBiotech to speak to all 15 winners and hear their passion, progress and panache,” said Ben Adams, Senior Editor of FierceBiotech. “Each company brought something different, exciting and potentially life-changing for myriad patients around the world across a host of diseases and disorders, using cutting-edge science, top-notch teams and a drive to genuinely make the world a better place, despite the risks and challenges that, as ever in biotech, lay ahead.”

It is a tremendous honor for Maze to be selected as a Fierce 15 company

“It is a tremendous honor for Maze to be selected as a Fierce 15 company, a designation that reflects the hard work and dedication of our entire team since the launch of the company earlier this year,” said Jason Coloma, Ph.D., chief executive officer of Maze. “Our entirely new approach to translating genetic insights into new medicines is unique, our approach to functional genomics is cutting-edge, and our team is united in our mission to make a transformative difference in the lives of many patients. It is a privilege to be a part of the 2019 ‘Fierce 15’ class, and one we could not be more delighted to hold.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 17th annual Fierce 15 selection.

An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech

FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.

About Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for a number of genetically defined diseases. Maze is focused on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics and an array of drug discovery approaches. The Maze platform reveals modifier genes that confer protection, and provides deeper understanding of the target biology and how these targets can be best targeted with drug therapies. Maze was launched in 2019 by Third Rock Ventures, with funding from ARCH Venture Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors. Maze is based in South San Francisco. For more information please visit http://mazetx.com.

Media Contact

Rebecca Willumson
FierceBiotech
202-824-5050
rwillumson@questex.com

Katie Engleman, 1AB
katie@1abmedia.com